Juan

The post on acsh.org links to the wrong study. The correct study is here:

http://www.nejm.org/doi/full/10.1056/NEJMoa1615664

Best,

Marilyn Mann

From: Evidence based health (EBH) [mailto:[log in to unmask]] On Behalf Of Juan Gérvas
Sent: Thursday, April 20, 2017 5:06 PM
To: [log in to unmask]
Subject: Repatha (evolocumad) EBM?

Repatha (evolocumad) (inyectable para colesterol). No "salva" vidas, mismos muertos. < 1,5% infartos a 2 mill $.
Repatha (evolocumad) does not "save lives", same deaths. Prevents 1.5% of major cardiac events, at 2 mill $ cost.
http://www.healthnewsreview.org/…/no-surprise-repatha-real…/

-and follow the market
http://acsh.org/news/2017/03/20/amgens-new-cholesterol-drug-repatha-godsend-or-boat-anchor-%E2%80%93-market-knows-11020
(today Amgen stocks 162.04 $)

-un saludo juan gérvas @JuanGrvas